Evidence map›Paper›PMID 34845451›Full record

ArticlebioRxiv : the preprint server for biology2021

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities.

Yaozong Chen, Lulu Sun, Irfan Ullah, Guillaume Beaudoin-Bussières, Sai Priya Anand, Andrew P Hederman, William D Tolbert, Rebekah Sherburn, Dung N Nguyen, Lorie Marchitto and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 2 countries.

Yaozong ChenInfectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
Lulu SunLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Irfan UllahDepartment of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA.
Guillaume Beaudoin-BussièresCentre de recherche du CHUM. Montreal, QC H2X 0A9, Canada.
Sai Priya AnandCentre de recherche du CHUM. Montreal, QC H2X 0A9, Canada.
Andrew P HedermanThayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.
William D TolbertInfectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
Rebekah SherburnInfectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
Dung N NguyenInfectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
Lorie MarchittoCentre de recherche du CHUM. Montreal, QC H2X 0A9, Canada.
Shilei DingCentre de recherche du CHUM. Montreal, QC H2X 0A9, Canada.
Di WuBiophysics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, 20892.
Yuhong LuoLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Suneetha GottumukkalaInfectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
Sean MoranBiomedical Instrumentation Center, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD, 20814, USA.
Priti KumarDepartment of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA.
Grzegorz PiszczekBiophysics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, 20892.
Walther MothesDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.
Andrés FinziCentre de recherche du CHUM. Montreal, QC H2X 0A9, Canada.
Pradeep D UchilDepartment of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.
Frank J GonzalezLaboratory of Metabolism, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
Marzena PazgierInfectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
Uniformed Services University of the Health Sciences · USCentre Hospitalier de l’Université de Montréal · CAYale University · USNational Cancer Institute · USDartmouth College · USNational Institutes of Health · US

Funding

Structure and Dynamics of the SARS-CoV-2 Spike ProteinR01AI163395 · NIAID · YALE UNIVERSITY · PI MOTHES, WALTHER H · 2021 to 2025
$4.1M
NIAID NIH HHS R01 AI163395
6 · The paper itself

Abstract

Soluble Angiotensin-Converting Enzyme 2 (ACE2) constitutes an attractive antiviral capable of targeting a wide range of coronaviruses utilizing ACE2 as their receptor. Here, using structure-guided approaches, we developed divalent ACE2 molecules by grafting the extracellular ACE2-domain onto a human IgG1 or IgG3 (ACE2-Fc). These ACE2-Fcs harbor structurally validated mutations that enhance spike (S) binding and remove angiotensin enzymatic activity. The lead variant bound tightly to S, mediated

Identifiers

PMID34845451
PMCPMC8629194
OpenAlexW3216671383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.